Positive Clinical Results from TPST-1120 Phase 1 Trial for Advanced Solid Tumors Published in Cancer Research Journal

TPST-1120, a novel oral PPAR⍺ inhibitor, has shown promising results in treating cancers that are resistant to PD-1 inhibitors and those with weakened immune systems. Following encouraging randomized study outcomes, Tempest Therapeutics, a clinical-stage biotech firm, is progressing TPST-1120 to a pivotal Phase 3 trial for hepatocellular carcinoma (HCC). The positive clinical findings from the Phase 1 trial of TPST-1120 were published in Cancer Research Communications, highlighting the drug's effectiveness as a standalone treatment or in combination with nivolumab. The drug was found to be well-tolerated and showed potential in shrinking tumors in patients with advanced solid tumors, including those who had not responded to PD-1 inhibitors. 

Dr. Sam Whiting, Tempest's chief medical officer, noted the significance of the Phase 1 study, which exhibited anti-tumor activity across various cancer types, reinforcing the belief in PPARα inhibition as a groundbreaking strategy for cancer treatment. The study involved 35 patients, with 20 receiving TPST-1120 as a monotherapy and 15 in combination with nivolumab. The drug demonstrated a favorable safety profile, with a majority of the observed toxicities being low-grade. 

Notably, stable disease was observed in over half of the patients treated with monotherapy, and tumor shrinkage was seen in 21% of them. In combination with nivolumab, TPST-1120 showed an objective response rate of 23% across all dosage levels and 30% at the highest two dosage levels, indicating a potential dose-dependent effect. The drug's impact on PPARα-associated immune gene expression in whole blood specimens was also analyzed, with changes correlating to clinical outcomes in patients with partial responses. 

TPST-1120 is a small molecule developed to target cancer cells directly and to modulate the tumor microenvironment by affecting immune suppressive cells and angiogenesis. In an ongoing global Phase 1b/2 study combining TPST-1120 with atezolizumab and bevacizumab for first-line HCC patients, the drug demonstrated superiority over the standard treatment in multiple study endpoints. Tempest Therapeutics, headquartered in Brisbane, California, is advancing a diverse pipeline of small molecule therapies with tumor-targeted and immune-mediated mechanisms. The company's programs are in various stages of development, from early research to late-stage clinical trials. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!